Michael Gelband’s Marker Therapeutics MRKR Stock Holding History

Michael Gelband’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,878	Closed	-$18K	–	2509
2021 Q4	$18K	Sell	1,878 -336	-15%	-$4.46K	﹤0.01%	2086
2021 Q3	$37K	Sell	2,214 -2,162	-49%	-$44.3K	﹤0.01%	1993
2021 Q2	$122K	Buy	4,376 +3,298	+306%	+$86.8K	﹤0.01%	2106
2021 Q1	$24K	Buy	+1,078	New	+$24.7K	﹤0.01%	2054
2019 Q2	–	Sell	-3,875	Closed	-$256K	–	1256
2019 Q1	$256K	Buy	3,875 +1,285	+50%	+$75K	0.02%	502
2018 Q4	$144K	Buy	+2,590	New	+$189K	0.01%	297

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Michael Gelband's MRKR Position: Q1 2022 in Review

Michael Gelband sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 1,878 shares — an estimated $18K sold.

Michael Gelband first reported a position in MRKR in Q4 2018 and held it in 6 quarters. The position peaked at $256K in Q1 2019. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Michael Gelband reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Michael Gelband sold 1,878 Marker Therapeutics shares in Q1 2022, an estimated $18K.
Michael Gelband first reported a position in Marker Therapeutics in Q4 2018 and held it in 6 quarters.
Michael Gelband's Marker Therapeutics position peaked at $256K in Q1 2019.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.